Overview: Angiotensin II Marker Rapid TestIntroduction: The Angiotensin II Marker Rapid Test is a diagnostic tool designed to detect angiotensin II levels in serum or plasma samples, facilitating the screening of hypertension or kidney disorders. Associated with renal artery stenosis or heart failure, this cardiovascular disorder presents with high blood pressure, fatigue, and severe complications like stroke if untreated, particularly in individuals with chronic kidney disease or vascular issues. Per the 2023 American Heart Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in cardiology or nephrology settings. This rapid diagnostic falls under endocrinology and targets individuals with cardiovascular or renal symptoms, addressing the challenge of early detection to guide ACE inhibitors or dialysis. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: Angiotensin II Rapid Test.FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Beckman Coulter, this test advanced hormone detection, providing a rapid alternative to traditional assays.Purpose: The test screens for Angiotensin II to guide hypertension or kidney disorder diagnosis, assess cardiovascular status, and inform treatment and prevention strategies.Test Parameters: Presence of Angiotensin II, detected with reasonable specificity to indicate renal or vascular function, typically detectable in serum or plasma at abnormal levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report high blood pressure, fatigue, or recent kidney issues.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on high blood pressure, fatigue, prior kidney issues, or family history of cardiovascular disease, as well as any recent trauma or medication use.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders including stroke, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent ACE inhibitor use can affect results. Correlation with renin or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible hypertension or kidney disorder, necessitating further investigation like renin levels or cardiology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during stable periods.Specialist Consultation: Cardiologists or nephrologists should be consulted for case management, treatment planning, and coordination with cardiovascular disease programs.Additional Supporting Tests: Renin, creatinine, or ultrasound for confirmation.Test Limitations: The test may produce false positives in stress or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AHA Guidelines 2023, Journal of Cardiology 2024, Biochemistry 2025.